Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Huilai Zhang et al.|The Lancet Oncology|2023Cited by 55
Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de LinfoproliferativosLuis Malpica, Brady Beltrán|JCO Global Oncology|2021Cited by 32